Compare WKHS & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WKHS | IGC |
|---|---|---|
| Founded | 2007 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.4M | 31.2M |
| IPO Year | N/A | N/A |
| Metric | WKHS | IGC |
|---|---|---|
| Price | $5.07 | $0.28 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $21.00 | $4.13 |
| AVG Volume (30 Days) | 557.6K | ★ 979.4K |
| Earning Date | 11-10-2025 | 02-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,106,000.00 |
| Revenue This Year | $92.70 | $3.54 |
| Revenue Next Year | $34.00 | $15.12 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 16.73 | N/A |
| 52 Week Low | $5.01 | $0.25 |
| 52 Week High | $153.00 | $0.50 |
| Indicator | WKHS | IGC |
|---|---|---|
| Relative Strength Index (RSI) | 59.52 | 31.98 |
| Support Level | $5.20 | $0.29 |
| Resistance Level | $5.71 | $0.31 |
| Average True Range (ATR) | 0.49 | 0.02 |
| MACD | -0.19 | -0.00 |
| Stochastic Oscillator | 3.12 | 4.00 |
Workhorse Group Inc is a technology company with a vision to pioneer the transition to zero-emission commercial vehicles. Its focus is to provide sustainable and cost-effective solutions to the commercial transportation sector. It designs and manufactures all-electric delivery trucks and drone systems, including the technology that optimizes the way these vehicles operate. It's focused on a core competency of bringing electric delivery vehicle platforms to serve the last-mile delivery market. Its products are marketed under the Workhorse brand.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.